190 related articles for article (PubMed ID: 22612993)
1. Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.
Auweiler PW; Müller D; Stock S; Gerber A
Pharmacoeconomics; 2012 Jul; 30(7):537-49. PubMed ID: 22612993
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
3. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.
Pink J; Lane S; Hughes DA
Pharmacoeconomics; 2012 May; 30(5):413-29. PubMed ID: 22428718
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
Greenhalgh J; Bagust A; Boland A; Blundell M; Oyee J; Beale S; Dundar Y; Hockenhull J; Proudlove C; Chu P
Pharmacoeconomics; 2013 May; 31(5):403-13. PubMed ID: 23576017
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.
Lueza B; Aupérin A; Rigaud C; Gross TG; Pillon M; Delgado RF; Uyttebroeck A; Amos Burke GA; Zsíros J; Csóka M; Simonin M; Patte C; Minard-Colin V; Bonastre J
Eur J Health Econ; 2024 Mar; 25(2):307-317. PubMed ID: 37058173
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of rituximab in follicular lymphoma.
Johnston KM; Bolbocean C; Connors J; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274
[TBL] [Abstract][Full Text] [Related]
12. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
13. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of follicular non-Hodgkin's lymphoma.
Foster T; Miller JD; Boye ME; Russell MW
Pharmacoeconomics; 2009; 27(8):657-79. PubMed ID: 19712009
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Cvetković RS; Perry CM
Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy.
Hornberger J; Chien R; Friedmann M; Han L; Shewade A; Satram-Hoang S; Reyes C
Leuk Lymphoma; 2012 Dec; 53(12):2371-7. PubMed ID: 22591119
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]